1289 related articles for article (PubMed ID: 25693363)
1. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
Avci A; Demir K; Altunkeser BB
Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():56-67. PubMed ID: 25693363
[TBL] [Abstract][Full Text] [Related]
2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
Joseph L; Robinson JG
Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
[TBL] [Abstract][Full Text] [Related]
3. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
Ling H; Burns TL; Hilleman DE
Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
[TBL] [Abstract][Full Text] [Related]
4. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
Dragan S; Serban MC; Banach M
J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
[TBL] [Abstract][Full Text] [Related]
6. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
7. [Inhibition of the protein PCSK9 is a promising target in the prevention of cardiovascular disease].
Christiansen MK; Jensen HK
Ugeskr Laeger; 2015 Mar; 177(11):. PubMed ID: 25786699
[TBL] [Abstract][Full Text] [Related]
8. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
Shen L; Peng H; Xu D; Zhao S
Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
[TBL] [Abstract][Full Text] [Related]
9. PCSK9 antibodies: A new class of lipid-lowering drugs.
Gouni-Berthold I
Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
11. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
Paton DM
Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
[TBL] [Abstract][Full Text] [Related]
12. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value.
Tice JA; Kazi DS; Pearson SD
JAMA Intern Med; 2016 Jan; 176(1):107-8. PubMed ID: 26662572
[No Abstract] [Full Text] [Related]
13. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
Kohli P; Desai NR; Giugliano RP; Kim JB; Somaratne R; Huang F; Knusel B; McDonald S; Abrahamsen T; Wasserman SM; Scott R; Sabatine MS
Clin Cardiol; 2012; 35(7):385-91. PubMed ID: 22714699
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction.
Henry CA; Lyon RA; Ling H
Vasc Health Risk Manag; 2016; 12():163-9. PubMed ID: 27143910
[TBL] [Abstract][Full Text] [Related]
15. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
16. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang E
Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
[TBL] [Abstract][Full Text] [Related]
17. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
Hooper AJ; Burnett JR
Expert Opin Biol Ther; 2013 Mar; 13(3):429-35. PubMed ID: 23240807
[TBL] [Abstract][Full Text] [Related]
18. Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.
Devito F; Zito A; Ricci G; Carbonara R; Dentamaro I; Cortese F; Carbonara S; Ciccone MM
Pharmacol Res; 2015 Dec; 102():168-75. PubMed ID: 26455563
[TBL] [Abstract][Full Text] [Related]
19. PCSK9 antibodies for the treatment of hypercholesterolemia.
Gouni-Berthold I; Berthold HK
Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
[TBL] [Abstract][Full Text] [Related]
20. Management of hypercholesterolemia for prevention of atherosclerotic cardiovascular disease: focus on the potential role of recombinant anti-PCSK9 monoclonal antibodies.
Verma DR; Brinton EA
Rev Cardiovasc Med; 2014; 15(2):86-101; quiz 101. PubMed ID: 25051126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]